Abstract
HupA is a potent, reversible and selective inhibitor of AChE with a rapid absorption and penetration into the brain in animal tests. It exhibits memory-enhancing activities in animal and clinical trials. Compared to tacrine and donepezil, HupA possesses a longer duration of action and higher therapeutic index, and the peripheral cholinergic side effects are minimal at therapeutic doses. This review article deals with a comprehensive survey of the progress in chemical and pharmacological studies of HupA including the isolation and structure elucidation, pharmacological actions, total synthesis, SAR studies and the future development of HupA. Recently, it has been reported that HupA could reduce neuronal cell death caused by glutamate. The dual bio-activities of HupA would further enhance its value and potentiality as the therapeutic agent for Alzheimers disease.
Keywords: huperzine A, inhibitor of AChE, revesibile inhibitors if AChE, lycopoduim, HupA, Huperzia serrata, alzheimer s disease, glutamate, dual bio activities, neuronal cell death, structure elucidation, pharmacological actions, total synthesis, SAR studies, donepezil, brain receptor, learning, memory, cyvlohexanedione mono ethylene ketal 10, keto ester, pyridine derivatives, dimethyl 4 oxopimelate, recemic HupA, stereiselective michael aldok reaction, diastereomeric separation, chiral catalyst, natura HupA, enantioselective palladium catalyzed bicycloannulation, structure activity relationships, the anti AChE activities, zusammen together, entgegen, lithium aluminium hydride, enantiomer excess, tetramethylguanidine, rectus, sinister left
Current Medicinal Chemistry
Title: Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease
Volume: 7 Issue: 3
Author(s): D. L. Bai, X. C. Tang and X. C. He
Affiliation:
Keywords: huperzine A, inhibitor of AChE, revesibile inhibitors if AChE, lycopoduim, HupA, Huperzia serrata, alzheimer s disease, glutamate, dual bio activities, neuronal cell death, structure elucidation, pharmacological actions, total synthesis, SAR studies, donepezil, brain receptor, learning, memory, cyvlohexanedione mono ethylene ketal 10, keto ester, pyridine derivatives, dimethyl 4 oxopimelate, recemic HupA, stereiselective michael aldok reaction, diastereomeric separation, chiral catalyst, natura HupA, enantioselective palladium catalyzed bicycloannulation, structure activity relationships, the anti AChE activities, zusammen together, entgegen, lithium aluminium hydride, enantiomer excess, tetramethylguanidine, rectus, sinister left
Abstract: HupA is a potent, reversible and selective inhibitor of AChE with a rapid absorption and penetration into the brain in animal tests. It exhibits memory-enhancing activities in animal and clinical trials. Compared to tacrine and donepezil, HupA possesses a longer duration of action and higher therapeutic index, and the peripheral cholinergic side effects are minimal at therapeutic doses. This review article deals with a comprehensive survey of the progress in chemical and pharmacological studies of HupA including the isolation and structure elucidation, pharmacological actions, total synthesis, SAR studies and the future development of HupA. Recently, it has been reported that HupA could reduce neuronal cell death caused by glutamate. The dual bio-activities of HupA would further enhance its value and potentiality as the therapeutic agent for Alzheimers disease.
Export Options
About this article
Cite this article as:
Bai L. D., Tang C. X. and He C. X., Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease, Current Medicinal Chemistry 2000; 7 (3) . https://dx.doi.org/10.2174/0929867003375281
DOI https://dx.doi.org/10.2174/0929867003375281 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B
Central Nervous System Agents in Medicinal Chemistry Transseptal Access to the Left Atrium: Tips and Tricks to Keep it Safe Derived from Single Operator Experience and Review of the Literature
Current Cardiology Reviews Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections
Recent Patents on Nanomedicine Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease
Current Neurovascular Research G-Coupled Protein Receptors and Breast Cancer Progression: Potential Drug Targets
Mini-Reviews in Medicinal Chemistry New Tuberculosis Drugs in Development
Current Topics in Medicinal Chemistry Psychosocial Stress But Not Exercise Increases Cortisol and Reduces State Anxiety Levels in School Classes - Results from a Stressor Applicable in Large Group Settings
CNS & Neurological Disorders - Drug Targets Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Drug Candidates from Traditional Chinese Medicines
Current Topics in Medicinal Chemistry Non-Antidepressant Pharmacologic Long-Term Treatment of Panic Disorder
Current Clinical Pharmacology Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease)
Current Alzheimer Research Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry Elderly Patients with Migraine: An Open-Label Study on Prophylaxis Therapy with Levetiracetam
Central Nervous System Agents in Medicinal Chemistry